Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1Phase 1 1

Status

Recruiting 4Completed 3Withdrawn 2Active not recruiting 2

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Tumor-Agnostic 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 33Lymphoma, Follicular 19Lymphoma, Non-Hodgkin 16Lymphoma, Large B-Cell, Diffuse 10Lymphoma 10Lymphoma, Mantle-Cell 7Lymphoma, B-Cell, Marginal Zone 6Lymphoma, B-Cell 5Recurrence 4Neoplasms 3Leukemia, Hairy Cell 2Waldenstrom Macroglobulinemia 1Uveal Melanoma 1Tumor Lysis Syndrome 1Solid Tumors 1Solid Cancers 1Oncology Patients Receiving Chemotherapy 1Neoplasm, Residual 1Neoplasm Metastasis 1Melanoma 1Leukemia, Prolymphocytic, B-Cell 1Leukemia, Prolymphocytic 1Leukemia, Lymphoid 1Leukemia, B-Cell 1Leukemia 1Disease 1Colorectal Neoplasms 1Chromosome 17 deletion 1Carcinoma, Non-Small-Cell Lung 1Bronchiolitis Obliterans Syndrome 1

Interventions

Gemcitabine 109Paclitaxel 92Carboplatin 79pembrolizumab 75Bevacizumab 75Surveys and Questionnaires 70Docetaxel 69Cisplatin 67Nivolumab 48Exercise 48Capecitabine 48Cyclophosphamide 47Sorafenib 43Fluorouracil 43Irinotecan 42Pemetrexed 37Albumin-Bound Paclitaxel 35Radiotherapy 34Dexamethasone 34Blood Specimen Collection 34Oxaliplatin 31Leucovorin 31Erlotinib Hydrochloride 31trametinib 30130-nm albumin-bound paclitaxel 29Cetuximab 28Therapeutics 26Ipilimumab 26Standard of Care 25Methods 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Neoplasms × obinutuzumab × Clear all
NCT02315768 2025-09-15

Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.

University of California, San Diego

Phase 1/2 Completed
32 enrolled 9 charts
LymphoidOther hematologic neoplasm

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03406156 2024-08-06

A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

AbbVie

Phase 3 Completed
120 enrolled 14 charts
LymphoidOther hematologic neoplasm

Chromosome 17 deletion, Neoplasms, Tumor Lysis Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03113695 2022-07-05

Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter's Syndrome

University of California, San Diego

Phase 1 Completed
4 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡